Hala Borno

MD

Genitourinary oncologist

Dr. Hala Borno is an oncologist who cares for patients who have cancers along the urinary tract, including kidney, bladder, testicular and prostate cancer. She specializes in treating prostate cancer.

Borno's research focuses on understanding causes of inequalities in cancer prevention, treatment, outcomes and clinical research participation. She is interested in developing and studying new ways to address these causes of inequalities.

Borno earned her medical degree from the University of North Carolina at Chapel Hill School of Medicine. She completed a residency in internal medicine and a fellowship in medical oncology at UCSF, where she was selected chief oncology fellow. She is a member of the American Society of Clinical Oncology and Alliance for Clinical Trials in Oncology.

  • Education

    University of North Carolina at Chapel Hill School of Medicine, 2013

  • Residencies

    UCSF, Internal Medicine, 2016

  • Fellowships

    UCSF, Medical Oncology, 2018

  • Board Certifications

    Medical Oncology, American Board of Internal Medicine

    Internal Medicine, American Board of Internal Medicine

  • Academic Title

    Assistant Professor

Clinics I work with

Genitourinary Medical Oncology Clinic

Bakar Precision Cancer Medicine Building

1825 Fourth St., Sixth Floor
San Francisco, CA 94158

Prostate Cancer Center

Bakar Precision Cancer Medicine Building

1825 Fourth St., Sixth Floor
San Francisco, CA 94158

My reviews

5.0

Overall Experience
232 Reviews
Explained things in a way that was easy to understand
230 Reviews
Did the doctor pay attention to your concerns
232 Reviews
Gave easy to understand instructions about taking care of health problems or concerns
224 Reviews
Knew the important information about your medical history
227 Reviews
The provider showed respect for what you had to say
230 Reviews
The provider spent enough time with me
228 Reviews
Decorative Caduceus

Impact of Phone Call About Financial Reimbursement Program on Access to Cancer Clinical Trials

The point estimate and 95% confidence interval (CI) of the proportion will be obtained within each site, furthermore, by cancer type and by phase of the clinical trial within each site.

Recruiting

Decorative Caduceus

Community-Based Health Coach to Improve Access to Germline Genetic Testing Among African Americ...

The consent rate for each cohort will be defined as proportion of patients enrolled in the study who agree to undergo germline genetic testing with Color genomics. The point estimate and 90% confidence interval will be provided.

Recruiting

Share